NEW YORK (GenomeWeb News) — Gene Logic is “investigating the possibility” of selling “all or parts” of its Genomics business, a slight change in tactics from “considering strategic alternatives” for the unit, which is the language it used as recently as April.

 

Two months before that, the firm said it may create “a spin-off entity with a retained equity position or other alternative structures to capture value for Gene Logic.”